期刊文献+

Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy 被引量:8

Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy
下载PDF
导出
摘要 AIM: To investigate if and to what extent antiviral therapy influenced a broad panel of quantitative testing of liver function (QTLF).METHODS: Fifty patients with chronic hepatitis C were either treated with interferon (n = 8), interferon/ribavirin (n = 19) or peg-interferon/ribavirin (n = 23). Quantitative testing of liver function, including aminopyrine breath test (ABT), galactose elimination capacity (GEC), sorbitol clearance (SCI) and indocyanine green clearance (ICG)was performed before and 3 mo after initiation of antiviral therapy.RESULTS: After 3 mo of antiviral treatment, 36 patients showed normal transaminases and were negative for HCV-RNA, 14 patients did not respond to therapy. ABT and GEC as parameters of microsomal and cytosolic liver function were reduced in all patients before therapy initiation and returned to normal values in the 36 therapy responders after 3 mo. Parameters of liver perfusion (SCI and ICG) were not affected by antiviral therapy. In the 14 non-responders,no changes in QTLF values were observed during the treatment period.CONCLUSION: ICG and SCI remained unaffected in patients with chronic hepatitis C, while ABT and GEC were significantly compromised. ABT and GEC normalized in responders to antiviral therapy. Early determination of ABT and GEC may differentiate responders from non-responders to antivJral treatment in hepatitis C. MM: To investigate if and to what extent antiviral therapy influenced a broad panel of quantitative testing of liver function (QTLF). METHODS: Fifty patients with chronic hepatitis C were either treated with interferon (n = 8), interferon/ribavirin (n = 19) or peg-interferon/ribavirin (n = 23). Quantitative testing of liver function, including aminopyrine breath test (ABT), galactose elimination capacity (GEC), sorbitol clearance (SCI) and indocyanine green clearance (ICG) was performed before and 3 mo after initiation of antiviral therapy. RESULTS: After 3 mo of antiviral treatment, 36 patients showed normal transaminases and were negative for HCVRNA, 14 patients did not respond to therapy. ABT and GEC as parameters of microsomal and cytosolic liver function were reduced in all patients before therapy initiation and returned to normal values in the 36 therapy responders after 3 too. Parameters of liver perfusion (SCl and ICG) were not affected by antiviral therapy. In the 14 non-responders, no changes in QTLF values were observed during the treatment period. CONCLUSION: ICG and SCI remained unaffected in patients with chronic hepatitis C, while ABT and GEC were significantly compromised. ABT and GEC normalized in responders to antiviral therapy. Early determination of ABT and GEC may differentiate responders from non-responders to antiviral treatment in hepatitis C.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第35期5521-5524,共4页 世界胃肠病学杂志(英文版)
关键词 肝功能 慢性丙型肝炎 抗滤过性病原体 治疗方法 Aminopyrine breath test Galactose eliminationcapacity Indocyanine green clearance Sorbitol clearance Hepatitis C Interferon Ribavirin
  • 相关文献

参考文献27

  • 1[1]Okuda K.Hepatocellular carcinoma.J Hepatol 2000; 32:225-237
  • 2[2]Everson GT.Treatment of chronic hepatitis C in patients with decompensated cirrhosis.Rev Gastroenterol Disord 2004;S1:S31-38
  • 3[3]McHutchison JG,Poynard T,Esteban-Mur R,Davis GL,Goodman ZD,Harvey J,Ling MH,Garaud JJ,Albrecht JK,Patel K,Dienstag JL,Morgan T.International Hepatitis Interventional Therapy Group.Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.Hepatology 2002; 35:688-693
  • 4[4]Zeuzem S,Hultcrantz R,Bourliere M,Goeser T,Marcellin P,Sanchez-Tapias J,Sarrazin C,Harvey J,Brass C,Albrecht J.Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.J Hepatol 2004; 40:993-999
  • 5[5]Manns MP,McHutchison JG,Gordon SC,Rustgi VK,Shiffman M,Reindollar R,Goodman ZD,Koury K,Ling M,Albrecht JK.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet 2001; 358:958-965
  • 6[6]Fried MW,Shiffman ML,Reddy KR,Smith C,Marinos G,Goncales FL Jr,Haussinger D,Diago M,Carosi G,Dhumeaux D,Craxi A,Lin A,Hoffman J,Yu J.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med 2002; 347:975-982
  • 7[7]Shiffman ML.Management of patients with chronic hepatitis C virus infection and previous nonresponse.Rev Gastroenterol Disord 2004; S1:S22-30
  • 8[8]Herold C,Heinz R,Radespiel-Troeger M,Schneider HJ,Hahn EG,Schuppan D.Quantitative liver function in patients with cirrhosis due to chronic hepatitis C to assess disease severity.Liver 2001; 21:26-30
  • 9[9]Merkel C,Gatta A,Zoli M,Bolognesi M,Angeli P,Iervese T,Marchesini G,Ruol A.Prognostic value of galactose elimination capacity,aminopyrine breath test,and ICG clearance in patients with cirrhosis.Comparison with the Pugh score.Dig Dis Sci 1991; 36:1197-1203
  • 10[10]Merkel C,Marchesini G,Fabbri A,Bianco S,Bianchi G,Enzo E,Sacerdoti D,Zoli M,Gatta A.The course of galactose elimination capacity in patients with alcoholic cirrhosis:possible use as a surrogate marker for death.Hepatology 1996;24:820-823

同被引文献39

引证文献8

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部